Asthma in ChildrenNCT03282864
The Impact of Air Filtration on Asthmatic Children
A study testing Bedroom air filtered by an air filtration device to remove airborne pollutants in people with Asthma in Children, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine at 1 site in China.
Trial summary
This study uses a crossover study design to examine the impact of a two-week bedroom based indoor air filtration on the concentration of indoor airborne pollutants, personal exposure to airborne pollutants and health indicators among asthmatic children living in Shanghai, China Read more about this study
- Who is it for?
- Ages 5 to 14 years
- Conditions the study is for
- Asthma in Children
- What is being tested?
- Bedroom air filtered by an air filtration device to remove airborne pollutants
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 43 participants
- Where
- 1 siteChina
- Study dates
- 17 Jan 2017to Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 5 to 14 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- An eligible child is defined as:
- Aged between 5 and 14
- Have physician-diagnosed asthma
- Had at least one asthma attack during the past year
- An eligible household is defined as:
- Has an eligible child
- Located in Shanghai, China
Who cannot join
- Children who were current smokers or have diseases other than asthma are exclude from study participation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Impact of Air Filtration on Health Indicators of Asthmatic Children
This study uses a crossover study design to examine the impact of a two-week bedroom based indoor air filtration on the concentration of indoor airborne pollutants, personal exposure to airborne pollutants and health indicators among asthmatic children living in Shanghai, China
Read the detailed description
This study recruited asthmatic children aged 5 to 14 who were living in Shanghai, China. Every study subject had the air in their bedroom processed by an air filtration device (with a pre-filter, a HEPA filter and an active carbon filter) for two weeks (active comparator arm), processed by a placebo air filtration device (which did not possess the HEPA filter and active carbon filters) for two weeks (placebo arm), and underwent a two-week washout period (no use of air filtration device) between the two intervention periods. The doors and windows of the bedroom were instructed to be kept closed during the intervention periods. The sequence of being in the active comparator arm and the placebo arm was randomized for each subject. The subject, their guardian and researchers who have direct interaction with the study subjects do not know this sequence until after the end of the study.
The study protocol was approved by IRB at Shanghai First People's Hospital, Duke University and University of Wisconsin at Madison. A sample size of 40 was calculated using fractional exhaled nitric oxide (FeNO) as the primary outcome where statistical significance was set at 0.05, power at 90%, and between-subject variance and covariance were estimated from existing literature. Four additional subjects were added to the estimated sample size of 40 to account for potential dropouts. Subjects were recruited from patients who attended the outpatient clinic of the Pediatrics Department of Shanghai First People's Hospital (south section) by Dr. Zhen Li and Dr. Junfeng Zhang's team. Assent was obtained from all study subjects and written informed consent was obtained from their guardians.
During the study, Dr. Michael Bergin's team and Dr. Yinping Zhang's team installed the air filtration devices in the subject's bedroom and measured the indoor concentration, outdoor concentration and personal exposure to airborne pollutants including PM2.5, ozone and volatile organic compounds. Dr. James Schauer's team analyzed the physical, chemical and bioactivity of the airborne particles collected and had no direct contact with the study subjects.
Each subject attended 5 clinical visits at the Shanghai First People's Hospital (South Section) accompanied by their guardian where clinical assessment (of lung function, fractional exhaled nitric oxide, asthma symptom blood draw) was performed by Drs. Zhen Li and Feng Li's team, and the collection of biological media (urine, saliva and nasal fluid) was conducted by Dr. Junfeng (Jim) Zhang's team. In addition, subjects were instructed to measure the peak expiratory flow (PEF) at 7am and 9pm daily and recorded their asthma symptoms at home with the assistance from their guardian(s). The biological media (urine, saliva and nasal fluid) collected was subsequently analyzed by Dr. Junfeng (Jim) Zhang's team for health indicators.
Each subject had access to the result of clinical assessment and health indicator in biological media, as well as free consultation from the medical teams of Drs. Zhen Li and Feng Li. Every subject was remunerated with 1000RMB (equivalent to 152 US dollars) and given a peak expiratory flow meter (worth less than 10 US dollars). All information collected from study subjects were recorded under their subject ID number and kept confidential. Only de-identified data was shared between collaborating investigators. Statistical analysis including mixed-effects models will be conducted on the data collected.
- Conditions
- Asthma in Children
- Being tested
- Bedroom air filtered by an air filtration device to remove airborne pollutants
- Keywords
- asthma, air pollution, air filtration, indoor air quality, respiratory health
- Medical subject headings
- Asthma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bedroom air filtered by an air filtration device to remove airborne pollutantsDevice
The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
| Study group | Role | What they receive |
|---|---|---|
| Bedroom air filtered by an air filtration device | Active comparator | The air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks. Receives: Device: Bedroom air filtered by an air filtration device to remove airborne pollutants |
| Bedroom air filtered by a placebo air filtration device | Placebo comparator | The air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks. Receives: Device: Bedroom air filtered by an air filtration device to remove airborne pollutants |
What is being measured
The primary outcome is the main question the study is designed to answer.
Fractional exhaled nitric oxide (FeNO)
Fractional exhaled nitric oxide (FeNO) was measured using the NIOX machine
Measured: Change of FeNO after the end of the two-week intervention compared to the start of the two-week intervention period
Secondary outcomes (3)
Asthma symptoms
Asthma symptom was evaluated by the Asthma Control Test (ACT) questionnaire
Measured: Within 24 hours before the start of intervention and within 24 hours after the end of intervention
Peak expiratory flow (PEF)
The maximum speed of exhalation (PEF) was measured by a handheld PEF meter (Koka Peak Expiratory Flow Meter)
Measured: Measured at 7am and 9pm daily during the two-week intervention
Lung function
Lung function was assessed by spirometry (Jaeger MasterScreen™ PFT system) and impulse oscillometry (Jaeger MasterScreenTM IOS).
Measured: Within 24 hours before the start of intervention and within 24 hours after the end of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Sep 2017
- Study start17 Jan 2017
- Primary completion22 Apr 2017
- Study completionDec 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Asthma in ChildrenStudies of the same condition, open and under way.
- More trials run by Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Every study subject had the air in their bedroom processed by an air filtration device (with a pre-filter, a HEPA filter and an active carbon filter) for two weeks (active comparator arm), processed by a placebo air filtration device (which did not possess the HEPA filter and active carbon filters) for two weeks (placebo arm), and underwent a two-week washout period (no use of air filtration device) between the two intervention periods.
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Underwriters Laboratory, Inc, Duke University, Tsinghua University, University of Wisconsin, Madison
- Responsible party
- Principal investigator, Zhen Li, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Investigators
- Michael H. Bergin, PhD, Study director, Duke UniversityJunfeng Zhang, PhD, Principal investigator, Duke UniversityJames J. Schauer, PhD, Principal investigator, University of Wisconsin, MadisonYinping Zhang, PhD, Principal investigator, Tsinghua UniversityFeng Li, MD, Principal investigator, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03282864
- Sponsor's protocol ID
- [2016] 48
- Status last verified
- Mar 2020
- First submitted
- 24 Aug 2017
- Last updated
- 23 Mar 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Cui X, Li Z, Teng Y, Barkjohn KK, Norris CL, Fang L, Daniel GN, He L, Lin L, Wang Q, Day DB, Zhou X, Hong J, Gong J, Li F, Mo J, Zhang Y, Schauer JJ, Black MS, Bergin MH, Zhang J. Association Between Bedroom Particulate Matter Filtration and Changes in Airway Pathophysiology in Children With Asthma. JAMA Pediatr. 2020 Jun 1;174(6):533-542. doi: 10.1001/jamapediatrics.2020.0140.
PubMed 32250418Brehmer C, Norris C, Barkjohn KK, Bergin MH, Zhang J, Cui X, Teng Y, Zhang Y, Black M, Li Z, Shafer MM, Schauer JJ. The impact of household air cleaners on the oxidative potential of PM2.5 and the role of metals and sources associated with indoor and outdoor exposure. Environ Res. 2020 Feb;181:108919. doi: 10.1016/j.envres.2019.108919. Epub 2019 Nov 13.
PubMed 31753466
Study at a glance
From the registry record, last updated by the sponsor on 23 Mar 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Air Filtration on Health Indicators of Asthmatic Children
- ClinicalTrials.gov ID
- NCT03282864
- Acronym / sponsor ID
- [2016] 48
- Conditions
- Asthma in Children
- Keywords
- asthma, air pollution, air filtration, indoor air quality, respiratory health
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 43 participants (actual)
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineUniversity, hospital or other
- Collaborators
- Underwriters Laboratory, Inc, Duke University, Tsinghua University, University of Wisconsin, Madison
- Study start
- 17 Jan 2017 (actual)
- Primary completion
- 22 Apr 2017 (actual)
- Study completion
- Dec 2020 (estimated)
- First posted
- 14 Sep 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study uses a crossover study design to examine the impact of a two-week bedroom based indoor air filtration on the concentration of indoor airborne pollutants, personal exposure to airborne pollutants and health indicators among asthmatic children living in Shanghai, China
Detailed description
This study recruited asthmatic children aged 5 to 14 who were living in Shanghai, China. Every study subject had the air in their bedroom processed by an air filtration device (with a pre-filter, a HEPA filter and an active carbon filter) for two weeks (active comparator arm), processed by a placebo air filtration device (which did not possess the HEPA filter and active carbon filters) for two weeks (placebo arm), and underwent a two-week washout period (no use of air filtration device) between the two intervention periods. The doors and windows of the bedroom were instructed to be kept closed during the intervention periods. The sequence of being in the active comparator arm and the placebo arm was randomized for each subject. The subject, their guardian and researchers who have direct interaction with the study subjects do not know this sequence until after the end of the study.
The study protocol was approved by IRB at Shanghai First People's Hospital, Duke University and University of Wisconsin at Madison. A sample size of 40 was calculated using fractional exhaled nitric oxide (FeNO) as the primary outcome where statistical significance was set at 0.05, power at 90%, and between-subject variance and covariance were estimated from existing literature. Four additional subjects were added to the estimated sample size of 40 to account for potential dropouts. Subjects were recruited from patients who attended the outpatient clinic of the Pediatrics Department of Shanghai First People's Hospital (south section) by Dr. Zhen Li and Dr. Junfeng Zhang's team. Assent was obtained from all study subjects and written informed consent was obtained from their guardians.
During the study, Dr. Michael Bergin's team and Dr. Yinping Zhang's team installed the air filtration devices in the subject's bedroom and measured the indoor concentration, outdoor concentration and personal exposure to airborne pollutants including PM2.5, ozone and volatile organic compounds. Dr. James Schauer's team analyzed the physical, chemical and bioactivity of the airborne particles collected and had no direct contact with the study subjects.
Each subject attended 5 clinical visits at the Shanghai First People's Hospital (South Section) accompanied by their guardian where clinical assessment (of lung function, fractional exhaled nitric oxide, asthma symptom blood draw) was performed by Drs. Zhen Li and Feng Li's team, and the collection of biological media (urine, saliva and nasal fluid) was conducted by Dr. Junfeng (Jim) Zhang's team. In addition, subjects were instructed to measure the peak expiratory flow (PEF) at 7am and 9pm daily and recorded their asthma symptoms at home with the assistance from their guardian(s). The biological media (urine, saliva and nasal fluid) collected was subsequently analyzed by Dr. Junfeng (Jim) Zhang's team for health indicators.
Each subject had access to the result of clinical assessment and health indicator in biological media, as well as free consultation from the medical teams of Drs. Zhen Li and Feng Li. Every subject was remunerated with 1000RMB (equivalent to 152 US dollars) and given a peak expiratory flow meter (worth less than 10 US dollars). All information collected from study subjects were recorded under their subject ID number and kept confidential. Only de-identified data was shared between collaborating investigators. Statistical analysis including mixed-effects models will be conducted on the data collected.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Every study subject had the air in their bedroom processed by an air filtration device (with a pre-filter, a HEPA filter and an active carbon filter) for two weeks (active comparator arm), processed by a placebo air filtration device (which did not possess the HEPA filter and active carbon filters) for two weeks (placebo arm), and underwent a two-week washout period (no use of air filtration device) between the two intervention periods.
| Arm | Type | Receives |
|---|---|---|
| Bedroom air filtered by an air filtration device | Active comparator | Device: Bedroom air filtered by an air filtration device to remove airborne pollutantsThe air in the bedroom of study subjects in the active comparator arm was filtered by an air filtration device which processed air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter. The duration of being in the active comparator arm was 2 weeks. |
| Bedroom air filtered by a placebo air filtration device | Placebo comparator | Device: Bedroom air filtered by an air filtration device to remove airborne pollutantsThe air in the bedroom of subjects in the placebo arm was filtered by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. The duration of being in the placebo arm was 2 weeks. |
Who may qualify
- Ages
- 5 to 14 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- Aged between 5 and 14
- Have physician-diagnosed asthma
- Had at least one asthma attack during the past year
- Has an eligible child
- Located in Shanghai, China
Key exclusion criteria (1 listed)
- Children who were current smokers or have diseases other than asthma are exclude from study participation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bedroom air filtered by an air filtration device to remove airborne pollutantsThe air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study. | Device | Bedroom air filtered by a placebo air filtration device, Bedroom air filtered by an air filtration device |
Primary outcome
Fractional exhaled nitric oxide (FeNO)
Time frame: Change of FeNO after the end of the two-week intervention compared to the start of the two-week intervention period
Fractional exhaled nitric oxide (FeNO) was measured using the NIOX machine
3 secondary outcomes
Asthma symptoms
Time frame: Within 24 hours before the start of intervention and within 24 hours after the end of intervention
Peak expiratory flow (PEF)
Time frame: Measured at 7am and 9pm daily during the two-week intervention
Lung function
Time frame: Within 24 hours before the start of intervention and within 24 hours after the end of intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Mar 2020.
- Derived from this study: PubMed 32250418Cui X, Li Z, Teng Y, Barkjohn KK, Norris CL, Fang L, Daniel GN, He L, Lin L, Wang Q, Day DB, Zhou X, Hong J, Gong J, Li F, Mo J, Zhang Y, Schauer JJ, Black MS, Bergin MH, Zhang J. Association Between Bedroom Particulate Matter Filtration and Changes in Airway Pathophysiology in Children With Asthma. JAMA Pediatr. 2020 Jun 1;174(6):533-542. doi: 10.1001/jamapediatrics.2020.0140.
- Derived from this study: PubMed 31753466Brehmer C, Norris C, Barkjohn KK, Bergin MH, Zhang J, Cui X, Teng Y, Zhang Y, Black M, Li Z, Shafer MM, Schauer JJ. The impact of household air cleaners on the oxidative potential of PM2.5 and the role of metals and sources associated with indoor and outdoor exposure. Environ Res. 2020 Feb;181:108919. doi: 10.1016/j.envres.2019.108919. Epub 2019 Nov 13.
- Individual participant dataSharing planned: Undecided
Related trials for Asthma in Children
Not yet recruiting
Asthma Ctrl SMART Trial
Asthma in Children, Asthma Chronic
Not yet recruiting
Artificially Intelligent Robot Control
Asthma in Children, Artificial Intelligence
Not yet recruiting
Bilevel Positive Airway Pressure (BPAP) for Severe Asthma
Pediatric Asthma, Acute Asthma
Recruiting
Effects of Tele-rehabilitation-Guided Qigong on Children and Adolescents With Asthma
Asthma Childhood
Enrolling by invitationObservational study
Investigating Novel Strategies in Pediatric Immune Responses and Microbiome Environment: Comprehensive Lung Disease Investigation in Children.
Lung Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael H. Bergin, PhD study director
Duke University
Junfeng Zhang, PhD principal investigator
Duke University
James J. Schauer, PhD principal investigator
University of Wisconsin, Madison
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Bedroom air filtered by an air filtration device to remove airborne pollutants in people with Asthma in Children, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 23 Mar 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Fractional exhaled nitric oxide (FeNO) (time frame: Change of FeNO after the end of the two-week intervention compared to the start of the two-week intervention period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03282864, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Mar 2020.